Combined Romosozumab and Raloxifene treatment targets impaired bone quality in a male murine model of diabetic kidney disease
Bone · 2025
DOI: 10.1016/j.bone.2025.117415 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bone, 2025. Verfasst von Rachel Kohler und 5 weiteren Autor:innen. Beteiligte Einrichtung: Weldon School of Biomedical Engineering, Purdue University, Indianapolis, IN, United States. Hauptthemen laut MEDLINE: Raloxifene Hydrochloride, Antibodies, Monoclonal, Diabetic Nephropathies, Bone and Bones. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: BLRD VA, NIAMS NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Comorbid diabetes and chronic kidney disease create a complex disease state with multi-faceted impacts on bone health, primarily reduced bone mass and tissue quality. To reduce fracture risk in this growing population, interventions are needed that target both bone mass and quality. Romosozumab (Romo) is an FDA-approved sclerostin inhibitor that has been shown to increase bone mass and strength in a murine model of combined diabetes and CKD (DKD), while Raloxifene (RAL) is a mild anti-resorptive used to treat osteoporosis that has also been shown to increase bone mechanical properties by increasing bone bound water content. We aimed to test whether combined RAL and Romo treatment could improve bone quality in our murine model of DKD more than either treatment alone. Using a previously established streptozotocin- and adenine-diet-induced model, male, C57BL/6J mice were randomly divided into four treatment groups and given daily subcutaneous injections of 100 μL vehicle (phosphorus buffered saline, PBS) or 0.5 mg/kg RAL. In addition, two groups were also given a weekly dose of Romo (10 mg/kg). Overall, Romo increased whole-bone strength and RAL improved tissue-level mechanical properties. Combined RAL-Romo treatment led to significantly higher cortical and trabecular bone mass compared to untreated controls. These morphological improvements created corresponding improvements in cortical bending strength and vertebral trabecular compression strength. These results suggest that combined RAL-Romo treatment provides both mass and quality improvements to DKD bone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Weldon School of Biomedical Engineering, Purdue University, Indianapolis, IN, United States.
- Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, United States.
- Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, United States; Roudebush Veterans Administration Medical Center, Indianapolis, IN, United States.
- Weldon School of Biomedical Engineering, Purdue University, Indianapolis, IN, United States; Roudebush Veterans Administration Medical Center, Indianapolis, IN, United States. Electronic address: jmwalla@iu.edu.
Förderung
- BLRD VA
- NIAMS NIH HHS
- National Institutes of Health
- U.S. Department of Veterans Affairs
Zitieren
APA
Kohler, R., Segvich, D. M., Reul, O., Metzger, C. E., Allen, M. R., & Wallace, J. M. (2025). Combined Romosozumab and Raloxifene treatment targets impaired bone quality in a male murine model of diabetic kidney disease. Bone. https://doi.org/10.1016/j.bone.2025.117415
Vancouver
Kohler R, Segvich DM, Reul O, Metzger CE, Allen MR, Wallace JM. Combined Romosozumab and Raloxifene treatment targets impaired bone quality in a male murine model of diabetic kidney disease. Bone. 2025. doi:10.1016/j.bone.2025.117415
BibTeX
@article{Kohler2025,
author = {Kohler, Rachel and Segvich, Dyann M and Reul, Olivia and Metzger, Corinne E and Allen, Matthew R and Wallace, Joseph M},
title = {Combined Romosozumab and Raloxifene treatment targets impaired bone quality in a male murine model of diabetic kidney disease},
journal = {Bone},
year = {2025},
doi = {10.1016/j.bone.2025.117415}
}
EUVIMED